[go: up one dir, main page]

AR066379A1 - CARBOXILIC ACID AMIDAS ITS PREPARATION AND ITS USE AS MEDICATIONS - Google Patents

CARBOXILIC ACID AMIDAS ITS PREPARATION AND ITS USE AS MEDICATIONS

Info

Publication number
AR066379A1
AR066379A1 ARP080101851A ARP080101851A AR066379A1 AR 066379 A1 AR066379 A1 AR 066379A1 AR P080101851 A ARP080101851 A AR P080101851A AR P080101851 A ARP080101851 A AR P080101851A AR 066379 A1 AR066379 A1 AR 066379A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
amino
substituted
alkylcarbonyl
Prior art date
Application number
ARP080101851A
Other languages
Spanish (es)
Inventor
Wolfgang Wienen
Kai Gerlach
Annette Schuler-Metz
Herbert Nar
George Dahmann
Henning Priepke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR066379A1 publication Critical patent/AR066379A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicacion 1: Compuestos de la formula general (1) en los cuales D representa un sistema de anillos bicíclico sustituido de la formula (2a), (2b) o (2c) en donde K1 y K4, en cada caso independientemente uno de otro, significan un enlace, un grupo -CH2-, -CHR2a-, -CR2bR2c o un grupo -C(O), y en donde R2a/R2b/R2c, en cada caso de modo independiente entre sí, significan un átomo de fluor, un grupo hidroxi, alquil C1-5-oxi, amino, alquil C1-5-amino, di-alquil C1-5-amino, cicloalquilen C3-5-imino, alquil C1-5-carbonilamino, un grupo alquilo C1-5, que puede estar sustituido con 1-3 átomos de fluor, un grupo hidroxi-alquilo C1-5, alquil C1-5-oxi-alquilo C1-5, amino-alquilo C1-5, alquil C1-5-amino-aIquilo C1-5, di-alquil C1-5-amino-alquilo C1-5, cicloalquilen C4-7-imino-alquilo C1-5, carboxialquilo C0-5, alquil C1-5-oxicarbonil-alquilo C0-5, aminocarbonil-alquilo C0-5, alquil C1-5-aminocarbonil-alquilo C0-5, di-alquil C1-5-aminocarbonil-alquilo C0-5 o un grupo cicloalquilen C4-7- iminocarbonil-alquilo C0-5, en donde al mismo tiempo los dos radicales R2b/R2c no pueden estar unidos al átomo de carbono del anillo a través de un heteroátomo, a excepcion de que -C(R2bR2c)- corresponda a un grupo -CF2, o R2a significa un grupo fenilo sustituido con fluor, cloro , bromo, metilo, metoxi, amino o nitro o heteroarilo monocíclico, o dos radicales R2b/R2c, junto con el átomo de carbono del anillo, pueden formar un carbociclo saturado de 3, 4, 5, 6 o 7 miembros o un anillo de ciclopenteno, ciclohexeno, oxetano, azetidina, tietano, tetrahidrofurano, pirrolidina, tetrahidrotiofeno, tetrahidropirano, piperidina, sulfuro de pentametileno, hexametilenimina, 1,3-dioxolano, 1,4-dioxano, hexahidropiridazina, piperazina, tiomorfolina, morfolina, 2-imidazolidinona, 2-oxazolidinona, tetrahidro-2(1H)-pirimidinona o [1,3]-oxazinan-2-ona, en donde sus grupos metileno pueden estar sustituidos con 1-2 grupos alquilo C1-3 o CF3, y/o sus grupos metileno, en la medida en que no estén unidos a un heteroátomo, pueden estar sustituidos con 1-2 átomos de fluor, y/o en el que un grupo -CH2, junto a un átomo de N, puede estar reemplazado por un grupo -CO, y/o sus grupos imino pueden estar sustituidos en cada caso con un grupo alquilo C1-3 o alquil C1-3-carbonilo, y/o en el que el átomo de azufre puede estar oxidado en un grupo sulfoxido o sulfona, K2 y K3, en cada caso independientemente uno de otro, significan un grupo -CH2, -CHR6a, -CR6bR6c o un grupo -C(O), en donde R6a/R6b/R6c en cada caso, de modo independiente entre sí, significan un grupo alquilo C1-5, que puede estar sustituido con 1-3 átomos de fluor, un grupo hidroxi-alquilo C1-5, alquil C1-5-oxi-alquilo C1-5, amino-alquilo C1-5, alquil C1-5-amino-alquilo C1-5, di-alquil C1-5-amino-alquilo C1-5, cicloalquilen C4-7-imino-alquilo C1-5, carboxi-alquilo C0-5, alquil C1-5-oxicarbonil-alquilo C0-5, aminocarbonil-alquilo C0-5, alquil C1-5-aminocarbonil-alquilo C0-5, di-alquil C1-5-aminocarbonil-alquilo C0-5 o un grupo cicloalquilen C4-7-iminocarbonil-alquilo C0-5, o dos radicales R6b/R6c, junto con el átomo de carbono del anillo, pueden formar un carbociclo saturado de 3, 4, 5, 6 o 7 miembros, o un anillo de ciclopenteno, ciclohexeno, oxetano, azetidina, tietano, tetrahidrofurano, pirrolidina, tetrahidrotiofeno, tetrahidropirano, piperidina, sulfuro de pentametileno, hexametilenimino, hexahidropiridazina, tetrahidro-2(1H)pirimidinona, [1,3]oxazinan-2-ona, en donde sus grupos metileno pueden estar sustituidos con 1-2 grupos alquilo C1-3 o CF3, y/o sus grupos metileno, en la medida en que no estén unidos a un heteroátomo, pueden estar sustituidos con 1-2 átomos de fluor, y/o en el que un grupo -CH2, junto a un átomo de nitrogeno, lo puede estar reemplazado por un grupo -CO, y/o sus grupos imino pueden estar sustituidos en cada caso con un grupo alquilo C1-3 o alquil C1-3-carbonilo, y/o en el que el átomo de azufre puede estar oxidado en un grupo sulfoxido o sulfona, con la condicion de que un heteroátomo incorporado por R6b o R6c no pueda ser separado por solo un átomo de carbono de X en la formula (1), y en la formula (2a) o (2b) o (2c) pueden estar presentes en total como máximo cuatro radicales seleccionados de R2a, R2b, R2c, R6a, R6b y R6c, y X significa un átomo de oxigeno o de azufre, un grupo CF2, sulfeno, sulfona o un grupo NR1, en el que R1 significa un átomo de hidrogeno o un grupo hidroxi, alquil C1-3-oxi, amino, alquil C1-3-amino, di-alquil C1-3-amino, un grupo alquilo C1-5, alquenil C2-5-CH2-, alquinil C2-5-CH2-, cicloalquilo C3-6, cicloalquenilo C4-6, oxetan-3-ilo, tetrahidrofuran-3-ilo, bencilo, alquil C1-5-carbonilo, trifluorometilcarbonilo, cicloalquil C3-6-carbonilo, alquil C1-5-sulfonilo, cicloalquil C3-6-sulfonilo, aminocarbonilo, alquil C1-5-aminocarbonilo, di-alquil C1-5-aminocarbonilo, alquil C1-5-oxicarbonilo, cicloalquilen C47-iminocarbonilo, en donde los grupos metileno y metilo que se encuentran en los grupos precedentemente mencionados pueden estar sustituidos adicionalmente con un grupo alquilo C1-3, carboxi, alcoxi C1-5-carbonilo, o con un grupo hidroxi, alquiloxi C1-5, amino, alquil C1-5-amino, dialquil C1-5-amino o cicloalquilen C4-7-imino, en la medida en que los grupos metileno o metilo no estén unidos directamente a un heteroátomo del grupo O, N o S, y/o uno a tres átomos de hidrogeno pueden estar reemplazados por átomos de fluor, en la medida en que los grupos metileno o metilo no estén unidos directamente a un heteroátomo del grupo O, N o S, y en el que A1 significa N o CR10, A2 significa N o CR11, A3 significa N o CR12; A4 significa N o CR12, A5 significa NH, azufre u oxigeno, en donde R10, R11 y R12, en cada caso independientemente uno de otro, significan un átomo de hidrogeno, fluor, cloro, bromo o yodo, o un grupo fenilo, alquilo C1-5, CF3, alquenilo C2-5, alquinilo C2-5, un grupo ciano, carboxi, alquil C1-5-oxicarbonilo, hidroxi, alquil C1-5-oxi, CF3O, CHF2O, CH2FO, amino, alquil C1-5-amino, di-alquil C1-5-amino o cicloalquilen C4-7-imino y R3 significa un átomo de hidrogeno, un grupo alquenilo C2-3 o alquinilo C2-3 o grupo alquilo C1-6 de cadena lineal o ramificado, en el que los átomos hidrogeno pueden estar reemplazados, en su totalidad o en parte, por átomos de fluor, y que, eventualmente, está sustituido con un grupo nitrilo, hidroxi, un grupo alcoxi C1-5, en el que los átomos de hidrogeno pueden estar reemplazados en su totalidad o en parte por átomos de fluor, un grupo aliloxi, propargiloxi, benciloxi, alquil C1-5-carboniloxi, alquiloxi C1-5-carboniloxi, carboxi-alquiloxi C1-3, alquiloxi C1-5-carbonil-alquiloxi C1-3, alquiloxi C1-8-carbonilamino, mercapto, alquil C1-3-sulfanilo, alquil C1-3-sulfinilo, alquil C1-3-sulfonilo, alquil C1-3-carbonilamino-alquil C1-3-sulfanilo, alquil C1-3-carbonilamino-alquil C1-3-sulfinilo, alquil C1-3-carbonilamino-alquil C1-3-sulfonilo, carboxi, alquiloxi C1-3-carbonilo, aliloxicarbonilo, propargiloxicarbonilo, benciloxicarbonilo, aminocarbonilo, alquil C1-3-aminocarbonilo, di-alquil C1-3-aminocarbonilo, cicloalquilen C3-6-iminocarbonilo, aminosulfonilo, alquil C1-3-aminosulfonilo, di-alquil C1-3-aminosulfonilo, cicloalquilen C3-6-iminosulfonilo, amino, alquil C1-3-amino, di-alquil C1-3-amino, alquil C1-5-carbonilamino, alquil C1-3-sulfonilamino, N-alquil C1-3-sulfonil-alquil C1-3-amino, cicloalquil C3-6-carbonilamino, aminocarbonilamino, alquil C1-3-aminocarbonilamino, di-alquil C1-3-aminocarbonilamino-, un grupo cicloalquileniminocarbonilamino de 4 a 7 miembros, benciloxicarbonilamino, fenilcarbonilamino o guanidino, un grupo carboxi, aminocarbonilo, alquil C1-4-aminocarbonilo, cicloalquil C3-6-aminocarbonilo, di-alquil C1-3-aminocarbonilo, alcoxi C1-4-carbonilo, cicloalquilen C4-6-iminocarbonilo, un grupo fenilo o heteroarilo, fenilcarbonil-alquilo C1-3, fenil-alquilo C1-3 o heteroaril-alquilo C1-3, que en la parte de fenilo o heteroarilo está sustituido, eventualmente una o más veces, con átomos de fluor, cloro o bromo, un grupo alquilo C1-3, amino, alquil C1-3-amino, di-alquil C1-3-amino, hidroxi, alquiloxi C1-4, mono-, di- o tri-fluorometoxi, benciloxi, carboxi-alquiloxi C1-3, alquiloxi C1-3-carbonil-alquiloxi C1-3, aminocarbonil-alquiloxi C1-3, alquil C1-3-aminocarbonil-alquiloxi C1-3, di-alquil C1-3-aminocarbonil-alquiloxi C1-3, un grupo cicloalquileniminocarbonil-alcoxi C1-3 de 4 a 7 miembros, carboxi, alquiloxi C1-3-carbonilo o alquiloxi C1-3-carbonilamino, un grupo cicloalquilo, cicloaquilenimino, cicloalquil-alquilo C1-3 o cicloalquilenimino-alquilo C1-3 de 3 a 7 miembros, en el que en la parte cíclica un grupo metileno puede estar reemplazado por un grupo -NH, eventualmente sustituido con un grupo alquilo C1-3 o alquil C1-3-carbonilo o un átomo de oxígeno y en el que, adicionalmente, un grupo metileno vecino a un grupo -NH, -Nalquil C1-3-carbonilo o -Nalquilo C1-3 puede estar reemplazado en cada caso por un grupo carbonilo o sulfonilo, con la condicion de que esté excluido un grupo cicloalquilenimino definido como antes, en el que dos átomos de nitrogeno están separados uno de otro por un grupo -CH2, R4 representa un átomo de hidrogeno o un grupo alquilo C1-3 o R3 y R4 forman, junto con el átomo de carbono al que están unidos, un grupo cicloalquilo C3-7, en donde uno de los grupos metileno del grupo cicloalquilo C3-7 puede estar reemplazado por un grupo imino, alquil C1-3-imino, acilimino o sulfonilimino, R5 representa un átomo de hidrogeno o un grupo alquilo C1-3, B un grupo de formulas (3) en la cual n representa el numero 1 o 2, R7 representa un átomo de hidrogeno o un grupo alquilo C1-3, hidroxi, alquiloxi C1-5-carbonilo, carboxi-alquilo C1-3, alquiloxi C1-3-carbonil-alquilo C1-3, amino o alquil C1-3-amino y R8, independientemente uno de otro, representan un átomo de hidrogeno, fluor, cloro, bromo o yodo, un grupo alquilo C1-3, en el que los átomos de hidrogeno pueden estar reemplazados, en su totalidad o en parte, por átomos de fluor, un grupo alquenilo C2-3 o alquinilo C2-3, un grupo hidroxi, alcoxi CClaim 1: Compounds of the general formula (1) in which D represents a substituted bicyclic ring system of the formula (2a), (2b) or (2c) wherein K1 and K4, in each case independently of each other, they mean a bond, a group -CH2-, -CHR2a-, -CR2bR2c or a group -C (O), and where R2a / R2b / R2c, in each case independently of each other, means a fluorine atom, a hydroxy group, C1-5-oxy alkyl, amino, C1-5-amino alkyl, di-C1-5-alkyl alkyl, C3-5 cycloalkylene, C1-5 alkylcarbonylamino, a C1-5 alkyl group, which it may be substituted with 1-3 fluorine atoms, a hydroxy-C1-5 alkyl, C1-5 alkyl-C1-5 alkyl, amino C1-5 alkyl, C1-5 alkyl-amino-C1-5 alkyl group , di-C1-5 alkyl-C1-5 alkyl-alkyl, C4-7 cycloalkylene-C1-5 alkyl, C0-5 carboxyalkyl, C1-5 alkyl-oxycarbonyl-C0-5 alkyl, aminocarbonyl-C0-5 alkyl , C1-5-alkylcarbonyl-C0-5 alkyl, di-C1-5-alkylcarbonyl-C0-5 alkyl or a C4-7 -imino cycloalkylene group C0-5 carbonyl-alkyl, wherein at the same time the two radicals R2b / R2c cannot be attached to the ring carbon atom through a heteroatom, except that -C (R2bR2c) - corresponds to a group -CF2 , or R2a means a phenyl group substituted with fluorine, chlorine, bromine, methyl, methoxy, amino or nitro or monocyclic heteroaryl, or two radicals R2b / R2c, together with the carbon atom of the ring, can form a saturated carbocycle of 3, 4, 5, 6 or 7 members or a ring of cyclopentene, cyclohexene, oxetane, azetidine, tiethane, tetrahydrofuran, pyrrolidine, tetrahydrothiophene, tetrahydropyran, piperidine, pentamethylene sulfide, hexamethyleneimine, 1,3-dioxolane, 1,4-dioxane, hexahydropyridazine, piperazine, thiomorpholine, morpholine, 2-imidazolidinone, 2-oxazolidinone, tetrahydro-2 (1H) -pyrimidinone or [1,3] -oxazinan-2-one, where their methylene groups may be substituted with 1-2 groups C1-3 alkyl or CF3, and / or its methylene groups, insofar as they are not attached to a heteroatom, they may be substituted with 1-2 fluorine atoms, and / or in which a -CH2 group, together with an N atom, may be replaced by a -CO group, and / or their imino groups may be substituted in each case with a C1-3 alkyl or C1-3 alkylcarbonyl group, and / or in which the sulfur atom may be oxidized in a sulfoxide or sulfone group, K2 and K3, in each case independently of each other , they mean a group -CH2, -CHR6a, -CR6bR6c or a group -C (O), where R6a / R6b / R6c in each case, independently of each other, means a C1-5 alkyl group, which can be substituted with 1-3 fluorine atoms, a hydroxy-C1-5 alkyl, C1-5 alkyl-C1-5 alkyl, amino C1-5 alkyl, C1-5 alkyl-amino-C1-5 alkyl group, di- C1-5 alkyl-C1-5 alkyl, C4-7 cycloalkylene-C1-5 alkyl, carboxy-C0-5 alkyl, C1-5 alkyl-oxycarbonyl-C0-5 alkyl, aminocarbonyl-C0-5 alkyl, C1-5-alkylcarbonyl-C0-5 -alkyl, di-C1-5 -alkylcarbonyl-C0-5 -alkyl or a group C4-7 cycloalkylene-iminocarbonyl-C0-5 alkyl, or two radicals R6b / R6c, together with the carbon atom of the ring, can form a saturated carbocycle of 3, 4, 5, 6 or 7 members, or a cyclopentene ring , cyclohexene, oxetane, azetidine, thiethane, tetrahydrofuran, pyrrolidine, tetrahydrothiophene, tetrahydropyran, piperidine, pentamethylene sulfide, hexamethyleneimino, hexahydropyridazine, tetrahydro-2 (1H) pyrimidinone, [1,3] oxazinan-2-sus-groups where methylene may be substituted with 1-2 C1-3 alkyl groups or CF3, and / or their methylene groups, insofar as they are not bound to a heteroatom, may be substituted with 1-2 fluorine atoms, and / or in that a -CH2 group, together with a nitrogen atom, can be replaced by a -CO group, and / or their imino groups can be substituted in each case with a C1-3 alkyl or C1-3 alkylcarbonyl group , and / or in which the sulfur atom may be oxidized into a sulfoxide or sulfone group, with the proviso that a he The thermoatome incorporated by R6b or R6c cannot be separated by only one carbon atom of X in the formula (1), and in the formula (2a) or (2b) or (2c) a maximum of four selected radicals can be present in total of R2a, R2b, R2c, R6a, R6b and R6c, and X means an oxygen or sulfur atom, a CF2 group, sulfen, sulfone or an NR1 group, in which R1 means a hydrogen atom or a hydroxy group, C1-3-oxy alkyl, amino, C1-3-amino alkyl, di-C1-3-amino alkyl, a C1-5 alkyl group, C2-5-CH2- alkenyl, C2-5-CH2- alkynyl, C3 cycloalkyl -6, C4-6 cycloalkenyl, oxetan-3-yl, tetrahydrofuran-3-yl, benzyl, C1-5 alkylcarbonyl, trifluoromethylcarbonyl, C3-6cycloalkylcarbonyl, C1-5 alkyl sulfonyl, C3-6 cycloalkyl sulfonyl, aminocarbonyl, C1-5-alkylcarbonyl, di-C1-5-alkylcarbonyl, C1-5-alkylcarbonyl, C47-iminocarbonyl cycloalkylene, wherein the methylene and methyl groups found in the aforementioned groups may be further substituted with a C1-3 alkyl, carboxy, C1-5 alkoxycarbonyl group, or with a hydroxy, C1-5 alkyloxy, amino, C1-5-amino alkyl, C1-5-dialkyl or C4- cycloalkylene group 7-imino, to the extent that the methylene or methyl groups are not directly linked to a heteroatom of the group O, N or S, and / or one to three hydrogen atoms may be replaced by fluorine atoms, to the extent that that the methylene or methyl groups are not directly linked to a heteroatom of the group O, N or S, and in which A1 means N or CR10, A2 means N or CR11, A3 means N or CR12; A4 means N or CR12, A5 means NH, sulfur or oxygen, where R10, R11 and R12, in each case independently of each other, mean a hydrogen, fluorine, chlorine, bromine or iodine atom, or a phenyl, alkyl group C1-5, CF3, C2-5 alkenyl, C2-5 alkynyl, a cyano group, carboxy, C1-5-oxycarbonyl alkyl, hydroxy, C1-5-oxy alkyl, CF3O, CHF2O, CH2FO, amino, C1-5 alkyl -amino, di-C1-5-amino or C4-7 -imino cycloalkylene and R3 means a hydrogen atom, a C2-3 alkenyl group or C2-3 alkynyl or straight or branched chain C1-6 alkyl group, in that the hydrogen atoms can be replaced, in whole or in part, by fluorine atoms, and which, if necessary, is substituted with a nitrile group, hydroxy, a C1-5 alkoxy group, in which the hydrogen atoms can be substituted in whole or in part by fluorine atoms, an allyloxy, propargiloxy, benzyloxy, C1-5 alkylcarbonyloxy, C1-5 alkyloxycarbonyloxy, carboxy C1-3 alkyloxy, alky loxy C1-5-carbonyl-C1-3 alkyloxy, C1-8 alkyloxycarbonylamino, mercapto, C1-3 alkyl sulfanyl, C1-3 alkyl sulfinyl, C1-3 alkyl sulfonyl, C1-3 alkylcarbonylamino alkyl C1-3-sulfanyl, C1-3 alkylcarbonylamino-C1-3-sulfinyl alkyl, C1-3 alkylcarbonylamino-C1-3-sulfonyl alkyl, carboxy, C1-3 alkyloxycarbonyl, allyloxycarbonyl, propargiloxycarbonyl, benzyloxycarbonyl, aminocarbonyl , C1-3-alkylcarbonyl, di-C1-3-aminocarbonyl, C3-6-iminocarbonyl, aminosulfonyl, C1-3-aminosulfonyl, di-C1-3-aminosulfonyl, C3-6-iminosulfonyl, cycloalkylene, amino , C1-3-amino alkyl, di-C1-3-amino alkyl, C1-5 alkylcarbonylamino, C1-3 alkyl sulfonylamino, N-C1-3 alkyl sulfonyl-C1-3-alkyl alkyl, C3- cycloalkyl 6-carbonylamino, aminocarbonylamino, C1-3-alkylcarbonylamino, di-C1-3-aminocarbonylamino-, a 4- to 7-membered cycloalkyleneiminocarbonylamino group, benzyloxycarbonylamino, phenylcarbonylamino or guanidino, a carb group oxy, aminocarbonyl, C 1-4 alkylcarbonyl, C 3-6 cycloalkylcarbonyl, di C 1-3 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 4-6 iminocarbonyl cycloalkylene, a phenyl or heteroaryl group, phenylcarbonyl alkyl C1-3, phenyl-C1-3 alkyl or heteroaryl-C1-3 alkyl, which in the phenyl or heteroaryl part is substituted, optionally one or more times, with fluorine, chlorine or bromine atoms, a C1-3 alkyl group , amino, C1-3-alkyl, di-C1-3-alkyl, hydroxy, C1-4 alkyloxy, mono-, di- or tri-fluoromethoxy, benzyloxy, carboxy-C1-3 alkyloxy, C1-3 alkyloxy- C1-3 carbonyl-alkyloxy, C1-3 aminocarbonyl-C1-3 alkyl, C1-3-aminocarbonyl-C1-3 alkyloxy, di-C1-3-aminocarbonyl-C1-3 alkyloxy group, a cycloalkyleneiminocarbonyl-C1-3 alkoxy group of 4 to 7 members, carboxy, C1-3 alkyloxycarbonyl or C1-3 alkyloxycarbonylamino, a cycloalkyl, cycloalkylimino, cycloalkyl-C1-3alkyl or cycloalkyleneimino-C1-3alkyl group of 3 to 7 members, wherein in the part cit Clicking on a methylene group may be replaced by a -NH group, optionally substituted with a C1-3 alkyl or C1-3 alkylcarbonyl group or an oxygen atom and in which, additionally, a methylene group neighboring a -NH group , -C1-3alkyl-carbonyl or -C1-3alkyl can be replaced in each case by a carbonyl or sulfonyl group, with the proviso that a cycloalkyleneimino group defined as before is excluded, in which two nitrogen atoms are separated from each other by a group -CH2, R4 represents a hydrogen atom or a C1-3 or R3 alkyl group and R4 form, together with the carbon atom to which they are attached, a C3-7 cycloalkyl group, wherein one of the methylene groups of the C3-7 cycloalkyl group may be replaced by an imino, C1-3-alkyl, acylimino or sulfonylimino group, R5 represents a hydrogen atom or a C1-3 alkyl group, B a group of formulas (3) in which n represents the number 1 or 2, R7 represents a hydrogen atom or a C1-3 alkyl, hydroxy, C1-5 alkyloxycarbonyl, carboxy C1-3 alkyl, C1-3 alkyloxycarbonyl C1-3 alkyl, amino or C1-3alkylamino and R8 group, independently of one of another, they represent a hydrogen, fluorine, chlorine, bromine or iodine atom, a C1-3 alkyl group, in which the hydrogen atoms may be replaced, in whole or in part, by fluorine atoms, a C2 alkenyl group -3 or C2-3 alkynyl, a hydroxy group, C alkoxy

ARP080101851A 2007-05-02 2008-04-30 CARBOXILIC ACID AMIDAS ITS PREPARATION AND ITS USE AS MEDICATIONS AR066379A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07107305 2007-05-02

Publications (1)

Publication Number Publication Date
AR066379A1 true AR066379A1 (en) 2009-08-12

Family

ID=39768821

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101851A AR066379A1 (en) 2007-05-02 2008-04-30 CARBOXILIC ACID AMIDAS ITS PREPARATION AND ITS USE AS MEDICATIONS

Country Status (3)

Country Link
AR (1) AR066379A1 (en)
TW (1) TW200902533A (en)
WO (1) WO2008135526A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5524852B2 (en) 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted amides, their production and use as pharmaceuticals
AR097279A1 (en) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd DERIVATIVES OF BENZIMIDAZOLIL-METIL UREA AS ALX RECEIVER AGONISTS
JP6466461B2 (en) 2014-02-03 2019-02-06 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Dihydropyrrolopyridine inhibitors of ROR gamma
EP3207043B3 (en) 2014-10-14 2019-10-02 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
JP6914257B2 (en) 2015-11-20 2021-08-04 ヴァイティー ファーマシューティカルズ，エルエルシー ROR-gamma modulator
TW202220968A (en) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 Modulators of ror-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF RORƳ
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited Imidazo-pyridine compounds as pad inhibitors
KR20200085836A (en) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pyrimidine derivatives as PD1/PD-L1 activation inhibitors
BR112020010322A2 (en) 2017-11-24 2020-11-17 Jubilant Episcribe Llc compound of the formula i; compound of the formula ia; compound of the formula ib; process for preparing compounds of formula i; pharmaceutical composition; method for the treatment and / or prevention of various diseases; use of compounds; method for treating cancer; and method for the treatment and / or prevention of a prmt5-mediated condition or a proliferative disorder or cancer
CN112105610B (en) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9a inhibitor
CN119462546A (en) * 2024-11-15 2025-02-18 南昌大学 A method for synthesizing benzodihetero five-membered ring

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040804A1 (en) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR
TWI422583B (en) * 2003-03-07 2014-01-11 參天製藥股份有限公司 Novel compound having 4-pyridylalkylthio group as substituent
BRPI0409136A (en) * 2003-04-09 2006-04-25 Japan Tobacco Inc pentacyclic heteroaromatic compound and medicinal use thereof
US7371743B2 (en) * 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors

Also Published As

Publication number Publication date
WO2008135526A1 (en) 2008-11-13
TW200902533A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
AR066379A1 (en) CARBOXILIC ACID AMIDAS ITS PREPARATION AND ITS USE AS MEDICATIONS
AR065852A1 (en) PIRROLIDINAMIDS REPLACED, USEFUL AS A FACTOR XA INHIBITOR
AR060945A1 (en) PROLINAMIDES REPLACED AND ITS USE AS MEDICATIONS
PE20080888A1 (en) HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1)
AR069596A1 (en) PLANT GROWTH REGULATOR
AR054627A1 (en) REPLACED GLICINAMIDS AS INHIBITORS OF SERINE PROTEASES AND OF THE XA FACTOR AND ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF THROMBROTIC DISEASES.
PE20121431A1 (en) PYRIMIDINE DERIVATIVES AS INHBIDORS OF THE PTK2 KINASE ENZYME
CO5690642A2 (en) PIRAZOLO COMPOUNDS [3,4-B] PIRIDINE, AND ITS USE AS PHOSPHODESTERASE INHIBITORS
PE20110196A1 (en) 5-ALKINYL-PYRIMIDINES
AR079648A1 (en) INHIBITORS OF HEPATITIS C VIRUS REPLICATION
AR048641A1 (en) ARTH- OR HETEROARILAMIDE ORTHOSUSTITUTED COMPOUNDS USEFUL AS ANTAGO-NISTAS OF THE PROSTAGLANDINAS E2 RECEIVER; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICAME
PE20080068A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINE AS INHIBITORS OF KINASE AURORA
CO6241108A2 (en) DERIVATIVES OF PIRROLOPIRIDINE AND ITS USE AS BACE INHIBITORS
PE20141005A1 (en) 1,3-OXAZINES AS INHIBITORS OF BACE1 AND / OR BACE2
PE20020961A1 (en) BICYCLE PYRIMIDINES AS INHIBITORS OF MATRIX METALOPROTEINASES
AR055100A1 (en) TRICYCLE BENZIMIDAZOLS AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
AR041170A1 (en) DERIVATIVES OF BENCIMIDAZOL, BENZOXAZOL AND BENZOTIAZOL
AR059778A1 (en) PIRROLOTRIAZINE COMPOUNDS INHIBITORS OF P38 KINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN GREAT VARIETY OF INFLAMMATORY PROCESSES.
PE20131197A1 (en) PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO5700754A2 (en) PIPERAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES
AR079231A1 (en) IMIDAZOQUINOLINE DERIVATIVES
PE20080205A1 (en) DERIVATIVES OF PYRAZOLOPYRIDINES SUBSTITUTED AS INHIBITORS OF TIROSIN KINASE Tie2
AR053228A1 (en) DERIVATIVES OF AZOL IN QUALITY OF LIPASE AND PHOSPHOLIPASE INIBIDORS
AR052568A1 (en) DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2
AR051794A1 (en) 3-AMINO-PIRAZOL [3,4B] PYRIDINS AS INHIBITORS OF PROTEINTIROSINQUINASAS, ITS PREPARATION AND USE AS A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FB Suspension of granting procedure